$74.99
This item has been third-party tested by accredited U.S. laboratories and confirmed to meet a minimum purity of 98% through rigorous verification standards.
Updated COA's
Secure Shipping Guaranteed
Verified for Purity
$74.99
Research Chemical products are third-party tested by MZ Biolabs, an independent laboratory based in Arizona. Each batch is analyzed to ensure accuracy, purity, and that all specifications are met.
AOD-9604 is a synthetic peptide derived from the C-terminus of human growth hormone (hGH), specifically spanning amino acids 177-191. Often referred to as the “lipolytic domain” of hGH, AOD-9604 has attracted significant interest in scientific circles for its potential effects on lipid metabolism and adipose tissue regulation. While not intended for human or veterinary use, AOD-9604 serves as an invaluable tool in research models focused on metabolic processes and fat reduction.
AOD-9604 has shown considerable promise in various animal studies, with rat studies highlighting its potential applications in fat metabolism, body composition, and overall metabolic health:
AOD-9604 is studied for its ability to stimulate lipolysis (the breakdown of fat) and inhibit lipogenesis (the formation of new fat cells) in research models. Studies have shown that AOD-9604 can positively influence fat cell activity, making it a key peptide in studies focused on fat loss.
Research on AOD-9604 has demonstrated its potential to improve body composition by promoting fat loss while preserving lean mass. It is being examined in animal models to understand its role in reducing body fat percentages.
Preliminary studies have suggested that AOD-9604 may improve insulin sensitivity, which is crucial for regulating blood sugar levels. This effect makes it an exciting area of research for those studying metabolic diseases and weight regulation.
In research settings, AOD-9604 has been shown to be well-tolerated with minimal side effects. Ongoing studies are exploring its long-term safety profile in controlled research environments, with promising results thus far.
1. Jensen MD. Potential role of new therapies in modifying cardiovascular risk in overweight patients with metabolic risk factors. Obesity (Silver Spring). 2006 Jun;14 Suppl 3:143S-149S. Doi: 10.1038/oby.2006.294. PMID: 16931496.
2. Stier, H., Vos, E., & Kenley, D. (2013). Safety and Tolerability of the Hexadecapeptide AOD-9604 in Humans. Journal of Endocrinology and Metabolism, 3(1-2), 7-15.
3. Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD-9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001 Dec;142(12):5182-9. Doi: 10.1210/endo. 142.12.8522. PMID: 11713213.
4. Ng, F. M., Sun, J., Sharma, L., Libinaka, R., Jiang, W. J., & Gianello, R. (2000). Metabolic studies of a synthetic lipolytic domain (AOD-9604) of human growth hormone. Hormone research, 53(6), 274-278.
You can purchase AOD-9604 directly from Research Chemical, where we offer high-quality, research-grade peptides backed by rigorous testing and excellent customer service.
No, AOD-9604 is strictly for research purposes only and is not approved for human or veterinary use.
Research suggests that AOD-9604 mimics certain fat-reducing properties of human growth hormone, targeting adipose tissue and influencing fat breakdown in controlled studies.
AOD-9604 is primarily used in research models to study fat metabolism, body composition, and metabolic health.
At Research Chemical, we specialize in high-quality research peptides, ensuring that each product is rigorously tested for purity and consistency. When you choose to buy AOD-9604 from us, you are guaranteed:
Don’t compromise on quality when conducting your research. Buy AOD-9604 from Research Chemical and experience the difference in product reliability and customer service. We back our products with a 60-day money-back guarantee, and our customer support team is always ready to assist you.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
1. Jensen MD. Potential role of new therapies in modifying cardiovascular risk in overweight patients with metabolic risk factors. Obesity (Silver Spring). 2006 Jun;14 Suppl 3:143S-149S. Doi: 10.1038/oby.2006.294. PMID: 16931496.
2. Stier, H., Vos, E., & Kenley, D. (2013). Safety and Tolerability of the Hexadecapeptide AOD-9604 in Humans. Journal of Endocrinology and Metabolism, 3(1-2), 7-15.
3. Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD-9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001 Dec;142(12):5182-9. Doi: 10.1210/endo. 142.12.8522. PMID: 11713213.
4. Ng, F. M., Sun, J., Sharma, L., Libinaka, R., Jiang, W. J., & Gianello, R. (2000). Metabolic studies of a synthetic lipolytic domain (AOD-9604) of human growth hormone. Hormone research, 53(6), 274-278.
Join our insider list for the latest research insights, product releases, and special offers—delivered straight to your inbox.
